TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$100 Million

Molecular Templates Inc

At-the-market Offering

Molecular Templates Inc

Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.